Hryniuk W M, Figueredo A, Goodyear M
Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Semin Oncol. 1987 Dec;14(4 Suppl 4):3-11.
Studies were analyzed to show the correlation of response with dose intensity of single-agent 5-fluorouracil (5-FU) against colorectal cancer, multiagent CMF (cyclophosphamide, methotrexate, 5-FU) regimens against advanced breast cancer, and adjuvant therapy in stage II breast cancer. In colorectal cancer studies, subgroups in which 5-FU was given by intravenous (IV) bolus, infusion, and orally were analyzed. One study reported delivered dose levels after reductions for toxicity. This allowed calculations of received dose intensity for the three dose levels, and comparison with projected dose intensities. The data suggest that the dose-intensity response line is steep, once a threshold dose intensity has been surpassed. An increase of only 100 mg/m2/wk of received dose intensity of 5-FU increased the response rate from 20% to 29%, which in relative terms was an increase of almost 50%. Received dose intensity may correlate with response, not only in groups of patients, but also in individual patients, and this may, in fact, be the most important application of the concept of dose intensity.
对各项研究进行分析,以显示单药5-氟尿嘧啶(5-FU)治疗结直肠癌、多药CMF(环磷酰胺、甲氨蝶呤、5-FU)方案治疗晚期乳腺癌以及II期乳腺癌辅助治疗的疗效与剂量强度之间的相关性。在结直肠癌研究中,分析了5-FU通过静脉推注、输注和口服给药的亚组。一项研究报告了因毒性而减量后的给药剂量水平。这使得能够计算三个剂量水平的实际接受剂量强度,并与预计剂量强度进行比较。数据表明,一旦超过阈值剂量强度,剂量强度-疗效曲线就很陡峭。5-FU实际接受剂量强度仅增加100 mg/m²/周,缓解率就从20%提高到29%,相对而言几乎增加了50%。实际接受剂量强度可能不仅在患者群体中,而且在个体患者中都与疗效相关,事实上,这可能是剂量强度概念最重要的应用。